the issue with eli lilly is the very competitive drug market, says short hills partners' weiss
Published 1 year ago • 7.5K plays • Length 3:35Download video MP4
Download video MP3
Similar videos
-
5:41
obesity drug could be a 'big upside' for eli lilly, says wells fargo's mohit bansal
-
2:24
eli lilly may have developed the greatest drug of all time, says jim cramer
-
4:22
fda approves a new alzheimer's drug from eli lilly
-
3:40
eli lilly's obesity drug will be a tailwind for the stock, says bmo's evan seigerman
-
5:22
eii lilly's weight-loss drug is 'much better' than others on the market, says wells fargo's bansal
-
1:09
lilly mixed signals
-
3:57
revolutionary approach to weight loss - zepbound (tirzepatide) explained
-
2:56
eli lilly to offer weight loss drug directly to qualifying customers at lower price
-
1:32
eli lilly's weight loss drug slashes the risk of developing diabetes in long-term trial
-
6:08
eli lilly ceo on slashing insulin prices, approval timelines for weight-loss and alzheimer's drugs
-
6:00
eli lilly's zepbound may be best-in-breed for weight loss drugs, says dr. kavita patel
-
0:59
eli lilly goes direct-to-consumer on weight loss drugs #shorts
-
2:10
i get stories every day from patients about how mounjaro is benefiting their lives: eli lilly ceo
-
4:03
eli lilly ceo: alzheimer's drug trial shows slowed disease progression by 40-60% in early patients
-
4:52
eli lilly ceo: we know there's high demand for weight-loss drugs and we're ready to meet it
-
4:14
eli lilly ceo david ricks on glp-1 and obesity drugs
-
4:23
two bullish calls on eli lilly
-
0:33
eli lilly unveils insulin that doesn’t work on poor people
-
1:47
promising data from eli lilly shows a significant slowdown in the pace of alzheimer's
-
5:24
eli lilly goes direct-to-consumer on weight loss drugs: what patients and investors need to know
-
7:19
jim cramer looks at eli lilly's outlook as the company's alzheimer drug goes through fda
-
1:44
eli lilly says price for humalog insulin is down 8.1%